Gilead Announces Promising Phase 2 HCV Treatment Results in Liver Transplant Patients
November 02, 2013 at 17:12 PM EDT
Gilead Sciences (NASDAQ: GILD ) today announced results from two Phase 2 studies evaluating an all-oral treatment regimen of the investigational once-daily nucleotide analogue sofosbuvir plus ribavirin (RBV)
